Systemic Lupus Erythematosus (SLE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Systemic Lupus Erythematosus (SLE) Market Outlook
Thelansis’s “Systemic Lupus
Erythematosus (SLE) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Systemic
Lupus Erythematosus (SLE) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
Systemic
Lupus Erythematosus (SLE) Overview
Systemic
Lupus Erythematosus (SLE) is a multifaceted autoimmune disease with many
clinical symptoms, diverse immunological and laboratory irregularities, and
variable outcomes. It predominantly affects women, with a male-to-female ratio
of about 1:9. Studies reveal a higher incidence and prevalence in women than
men, with rates approximately six times higher. In juvenile SLE patients in the
Western world, 5-year survival rates now range from 94% to 100%, but the
10-year survival rate remains somewhat lower, at 81% to 92%. However, this rate
drops to 65% in Asian patients with renal involvement. Age significantly
influences SLE, with its peak incidence typically occurring during the
reproductive years. Renal involvement is a common aspect of SLE, affecting 81%
of children and 46% of adults. For most patients, it becomes apparent within
two years of the disease’s onset, and the histological patterns of lupus
nephritis in children closely resemble those in adults.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment